All In Biotech

Drug Trial Radar · NCT00849108

Development of 1-Day Rest/Stress Cardiac PET Perfusion Imaging Protocol of BMS747158

A Phase 2, Open-Label, Randomized Multicenter Study for the Development of One-Day Rest/Stress Cardiac Positron Emission Tomography (PET) Perfusion Imaging Protocols of BMS747158

Last checked: Nov 20, 2026Latest source record: Oct 14, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

176

Actual

Start

Jan 2009

Primary completion

Jun 2010

Study completion Jun 2010

Sponsor

Lead sponsor
Lantheus Medical ImagingIndustry
Sponsor type
Industry
First posted
Feb 23, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Diagnostic
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main purpose of this study is to get more information on using BMS747158 (the study drug),a drug with small amounts of radioactivity to allow for heart imaging, during a PET scan which can then be compared to other images such as SPECT. The safety and quality of images will be studied.

Conditions

  • Ischemia

Interventions

  • BMS747158Drug

    dosages at rest and at stress were not to exceed a total of 14 mCi. Cohort 1: Patients received either 2 or 3 IV bolus injections of BMS747158: 1 at rest and 1 or 2 during stress, over a 1-day or 2-day period. Cohort 2: Patients to recieve IV bolus injections of BMS747158: For the Pharmacologic (Adenosine) Stress: * Doses at rest were to range between 2.9 and 3.4 mCi. * Doses under stress were to be a factor of 2.0 to 2.4 greater than the rest dose, resulting in a range of stress doses between 5.8 and 8.2 mCi. For the Exercise Stress: * Doses at rest were to range between 1.7 and 2.0 mCi. * Doses under stress were to be a factor of 3.0 to 3.6 greater than the rest dose, resulting in a range between 5.1 and 7.2 mCi.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cohort 1: Determination of Rest Dose: Dose Acquistion Time ProductTime frame: Dosing visit
  2. Cohort 2: Diagnostic Efficacy of One-day Rest/Stress BMS747158 PET MPI Sensitivity (SN) vs SPECT MPI SensitivityTime frame: Dosing visit
  3. Cohort 1: Determination of Ratio of Stress Dose to Rest DoseTime frame: Dosing visit
  4. Cohort 2: Diagnostic Efficacy of One-day Rest/Stress BMS747158 PET MPI Specificity (SP) vs SPECT MPI SpecificityTime frame: Dosing Visit

Locations

24 sites in 1 country. Site status is shown where the registry gives one.

  • Silicon Valley Medical Imaging

    Fremont, California

  • Scripps Memorial Hospital

    La Jolla, California

  • Cedars-Sinai Medical Center

    Los Angeles, California

  • UCLA Medical Plaza

    Los Angeles, California

  • Radiological Associates of Sacramento

    Sacramento, California

  • VA Healthcare System San Diego

    San Diego, California

  • Hartford Hospital

    Hartford, Connecticut

  • Yale University

    New Haven, Connecticut

  • Emory University Hospital

    Atlanta, Georgia

  • Primary Care Cardiology Research, Inc

    Ayer, Massachusetts

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Brigham & Women's Hospital

    Boston, Massachusetts

  • University of Michigan

    Ann Arbor, Michigan

  • Cardiovascular Consultants

    Kansas City, Missouri

  • Saint Louis University

    St Louis, Missouri

  • Washington University School of Medicine

    St Louis, Missouri

  • University of Medicine and Dentistry of New Jersey

    Newark, New Jersey

  • Holy Name Hospital

    Teaneck, New Jersey

  • Columbia University Medical Center

    New York, New York

  • St. Francis Hospital

    Roslyn, New York

  • University Hospital Case Medical Center

    Cleveland, Ohio

  • Midwest Cardiology Research Foundation

    Columbus, Ohio

  • Mountain States Health Alliance

    Johnson City, Tennessee

  • East Tennessee Clinical Research Institute

    Knoxville, Tennessee

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.